DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+11.29%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$244M
AUM Growth
+$244M
(+14%)
Cap. Flow
+$10.4M
Cap. Flow
% of AUM
4.28%
Top 10 Holdings %
Top 10 Hldgs %
46.31%
Holding
79
New
4
Increased
21
Reduced
24
Closed
3
Top Buys
| 1 |
argenx
ARGX
|
$2.91M |
| 2 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
$2.69M |
| 3 |
BLUE
bluebird bio
BLUE
|
$2.41M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
$2.01M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
$1.88M |
Top Sells
| 1 |
DexCom
DXCM
|
$2.57M |
| 2 |
Minerva Neurosciences
NERV
|
$1.31M |
| 3 |
LMNX
Luminex Corp
LMNX
|
$955K |
| 4 |
Larimar Therapeutics
LRMR
|
$906K |
| 5 |
AtriCure
ATRC
|
$757K |
Sector Composition
| 1 | Healthcare | 89.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $29M | 11.9% | 169,675 +11,000 | +7% | +$1.88M |
|
2
Stereotaxis
STXS
$261M
| $16.6M | 6.8% | 13,680,554 | – | – |
|
|
SAGE
3
DELISTED
Sage Therapeutics
SAGE
| $14M | 5.76% | 99,306 +3,306 | +3% | +$467K |
|
|
4
AtriCure
ATRC
$1.84B
| $10.3M | 4.23% | 293,729 -21,616 | -7% | -$757K |
|
|
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
| $8.54M | 3.51% | 306,119 | – | – |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $8.17M | 3.36% | 132,770 +1,000 | +0.8% | +$61.6K |
|
|
BPMC
7
DELISTED
Blueprint Medicines
BPMC
| $7.24M | 2.97% | 92,691 | – | – |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $6.86M | 2.82% | 138,264 +40,500 | +41% | +$2.01M |
|
|
ALDR
9
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $6.59M | 2.71% | 396,013 | – | – |
|
10
Akebia Therapeutics
AKBA
$833M
| $5.53M | 2.27% | 625,738 +15,000 | +2% | +$132K |
|
11
Ascendis Pharma
ASND
$11.8B
| $5.47M | 2.25% | 77,242 +3,497 | +5% | +$248K |
|
|
12
DexCom
DXCM
$29.5B
| $5.29M | 2.17% | 37,000 -18,000 | -33% | -$2.57M |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $5.04M | 2.07% | 41,008 -4,500 | -10% | -$553K |
|
14
ProQR Therapeutics
PRQR
$237M
| $5.04M | 2.07% | 260,336 +88,985 | +52% | +$1.72M |
|
15
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.98M | 2.04% | 652,086 +47,434 | +8% | +$362K |
|
|
16
argenx
ARGX
$43.6B
| $4.88M | 2% | 64,300 +38,351 | +148% | +$2.91M |
|
|
FOMX
17
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.63M | 1.9% | 808,000 +470,000 | +139% | +$2.69M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.54M | 1.86% | 98,547 +3,305 | +3% | +$152K |
|
19
Galapagos
GLPG
$2.07B
| $4.45M | 1.83% | 39,609 -1,000 | -2% | -$112K |
|
20
Kura Oncology
KURA
$686M
| $4.21M | 1.73% | 240,500 +1,000 | +0.4% | +$17.5K |
|
|
LMNX
21
DELISTED
Luminex Corp
LMNX
| $4.2M | 1.72% | 138,391 -31,500 | -19% | -$955K |
|
|
IMMU
22
DELISTED
Immunomedics Inc
IMMU
| $3.71M | 1.52% | 178,000 -5,000 | -3% | -$104K |
|
|
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
| $3.26M | 1.34% | 294,511 | – | – |
|
24
iShares Biotechnology ETF
IBB
$5.6B
| $3.18M | 1.31% | 26,100 | – | – |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $3.14M | 1.29% | 237,683 -56,679 | -19% | -$748K |
|